AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Preliminary clinical data indicate efficacy of Doxil against Kaposi's sarcoma. (liposome formulation of doxorubicin) (VIII International Conference on AIDS)
VIII International Conference on AIDS
Speaking at the VIII International Conference on AIDS/III STD World Congress, Amsterdam, the Netherlands, Frank D. Goebel, M.D., presented data from a Phase II open clinical trial in AIDS patients with Kaposi's sarcoma (KS).
Of 30 evaluable patients enrolled in the study, all patients treated with Doxil have responded to therapy following two courses of treatment.
Doxil, a new investigational drug developed and owned by Liposome Technology Inc. (LTI), Menlo Park, California, is a long-circulating Stealth liposome formulation of the anticancer drug doxorubicin hydrochloride.
Goebel reported that …
